HIV-1 Tat protein decreases dopamine transporter cell surface expression and vesicular monoamine transporter-2 function in rat striatal synaptosomes.

Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology
Narasimha M MiddeJun Zhu

Abstract

The dopamine (DA) transporter (DAT) and vesicular monoamine transporter (VMAT2) proteins interact as a biochemical complex to regulate dopaminergic neurotransmission. We have reported that HIV-1Tat(1-86) decreases the specific [(3)H]DA uptake and [(3)H]WIN 35,428 binding sites without a change in total DAT immunoreactivity in rat striatum (Zhu et al., 2009b). The present study determined the effects of Tat on DAT phosphorylation and trafficking, and vesicular [(3)H]DA uptake. Pre-incubation of rat striatal synaptosomes with the protein kinase C (PKC) inhibitor bisindolylmaleimide I (1 μM) completely blocked Tat(1-86)-induced reduction of [(3)H]DA uptake, indicating that Tat regulates DAT function through a PKC-dependent mechanism. After exposure of synaptosomes to Tat(1-86) (1 μM), DAT immunoreactivity was decreased in plasma membrane enriched fractions (P3) and increased in vesicle-enriched fractions (P4) relative to controls without change in total synaptosomal fractions (P2), suggesting that Tat-induced inhibition of DA uptake is attributable to DAT internalization. Although both DAT and VMAT2 proteins are essential for the regulation of DA disposition in synapse and cytosol, Tat inhibited the specific [(3)H]DA uptake into v...Continue Reading

References

Oct 4, 1993·Biochimica Et Biophysica Acta·G Rudnick, J Clark
Jul 1, 1993·Journal of Psychoactive Drugs·E P Larrat, S Zierler
May 14, 1996·Proceedings of the National Academy of Sciences of the United States of America·J D EricksonE Weihe
Apr 1, 2000·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Z LinG R Uhl
May 24, 2000·Journal of Neurovirology·L HudsonI Everall
May 24, 2000·Proceedings of the National Academy of Sciences of the United States of America·C SaundersA Galli
Sep 17, 2003·The Journal of Pharmacology and Experimental Therapeutics·Limen Chi, Maarten E A Reith
Aug 21, 2004·Brain : a Journal of Neurology·Gene-Jack WangJoanna S Fowler
Oct 7, 2004·Neuropharmacology·Nancy R Zahniser, Alexander Sorkin
Oct 27, 2004·Pharmacology & Therapeutics·Haley E Melikian
Jan 14, 2005·The Journal of Biological Chemistry·L'Aurelle A JohnsonMargaret E Gnegy
Sep 27, 2005·Neuropharmacology·Balachandra K Gorentla, Roxanne A Vaughan
Oct 11, 2005·Neuropharmacology·L'aurelle A JohnsonMargaret E Gnegy
Dec 5, 2006·European Journal of Pharmacology·Lisa S MiddletonLinda P Dwoskin
Jan 11, 2007·Annual Review of Pharmacology and Toxicology·Annette E FleckensteinGlen R Hanson
Apr 7, 2007·Synapse·Prasanna K ThwarJennifer J Linderman
Sep 4, 2007·Neurotoxicology·Janelle M SilversRosemarie M Booze
Dec 18, 2008·The Journal of Pharmacology and Experimental Therapeutics·Jun ZhuLinda P Dwoskin
Jan 9, 2009·CNS & Neurological Disorders Drug Targets·J Zhu, M E A Reith

❮ Previous
Next ❯

Citations

May 7, 2013·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Narasimha M MiddeJun Zhu
Dec 24, 2013·Virology Journal·Asen Bagashev, Bassel E Sawaya
Dec 30, 2014·Journal of Neuroinflammation·Anantha Ram Nookala, Anil Kumar
Dec 27, 2012·Molecular and Cellular Neurosciences·Angela H Shin, Stanley A Thayer
Feb 20, 2015·ACS Chemical Neuroscience·Yaxia YuanChang-Guo Zhan
Mar 10, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Scot McIntoshScott E Hemby
Aug 29, 2012·Neurobiology of Disease·Gladys ChompreRichard J Noel
Jan 22, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Narasimha M MiddeJun Zhu
Apr 7, 2017·Brain Sciences·Rossana ScutariStefano Aquaro
May 13, 2017·Brain, Behavior, and Immunity·James P KesbySvetlana Semenova
Sep 25, 2018·Cell Biochemistry and Function·Jéssica CampestriniAguinaldo Roberto Pinto
May 20, 2018·Scientific Reports·Sarah J BertrandRosemarie M Booze
Dec 31, 2019·PLoS Pathogens·David Alvarez-CarbonellJonathan Karn
Sep 3, 2020·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Sylvia FittingKurt F Hauser
Nov 12, 2015·Frontiers in Microbiology·Sonia MediouniSusana T Valente
Mar 16, 2018·Neurochemical Research·Matthew V GreenStanley A Thayer
Jun 14, 2020·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Jessica M IllenbergerRosemarie M Booze
Dec 7, 2018·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·R A NolanP J Gaskill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.